Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma-Target: Collection of Samples from Cancer Patients on Targeted Therapies or Immunotherapy
NCT03835520Active, not recruiting
- Start
- Jul 2018
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin icodec in cancer (2 arms). Primary endpoint: Efficacy of treatment against Cancer at 120 months. Started Jul 2018; status: active, not recruiting.
02
Drugs
insulin icodec
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03835520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835520.